FDA accepts supplemental biologics license application for Dupixent for EoE - Healio

Regeneron Pharmaceuticals Inc. and Sanofi announced that the FDA accepted for priority review a supplemental biologics license application for Dupixent 300 mg for adults and children aged 12 years and older with eosinophilic esophagitis. According to a releas…

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.Back to Healio Regeneron Pharmaceuticals Inc. and Sanof… [+2097 chars]

full article...